Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25866687 | 0.88 | SMN1; SMN2 (0.65) | MDM2ALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL29232726 | 0.87 | CCR6 (0.56) | MDM2ALDH1A1RAB9ANPC1ATM | |
| SCHEMBL8946445 | 0.87 | MDM2 (0.68) | MDM2ALDH1A1RAB9ANPC1ATM | |
| SCHEMBL9784691 | 0.87 | KDM4E (0.55) | MDM2ALDH1A1RAB9ANPC1ATM | |
| SCHEMBL28779576 | 0.86 | DCTPP1 (0.60) | MDM2ALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL4386607 | 0.85 | RAB9A (0.74) | MDM2ALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL4131672 | 0.85 | KDM4E (0.54) | MDM2ALDH1A1RAB9ANPC1ATM | |
| SCHEMBL9647875 | 0.85 | SMN1; SMN2 (0.74) | MDM2ALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL31339958 | 0.84 | RAB9A (0.60) | MDM2ALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL4426818 | 0.84 | RAB9A (0.60) | MDM2ALDH1A1RAB9ANPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5047542-A | Reaction of ketoester with unsaturated aldehyde or ketone | HOECHST CELANESE CORPORATION (US) | 1991-09-10 | — | — | US | claimed |
| US-4871859-A | REACTING KETOESTER WITH UNSATURATED ALDEHYDE OR KETONE AND AMMONIUM SALT IN SOLVENT AND DEHYDROGENATION CATALYST | HOECHST CELANESE CORPORATION | 1989-10-03 | — | — | US | claimed |
| WO-1989008103-A1 | PROCESS FOR PREPARING PYRIDINE CARBOXYLIC ACID ESTERS | HOECHST CELANESE CORPORATION (US) | 1989-09-08 | — | — | WO | claimed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480954-B1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-6110910-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTIRHEUMATIC AGENTS, ANTICARCINOGENIC AGENTS | DUPONT PHARMACEUTICALS (US) | 2000-08-29 | — | — | US | disclosed |
| US-5874441-A | TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| US-5639759-A | ORGAN TRANSPLANTATION; AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTIARTHRITIC AGENTS; ANTICANCER AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0716652-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5428040-A | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | MDM2 4677/4885ALDH1A1 2107/4885RAB9A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.